Bausch + Lomb and Alfa Instruments are also in the process of exploring regulatory requirements and approvals of the surgical dyes in other markets. For more information on VitreoCare, visit www ...

Bausch + Lomb is expanding its ophthalmology portfolio and pipeline, paying Novartis $1.75 billion to acquire a commercialized drug for dry eye disease along with two experimental eye products ...

New Products Will Focus on Dogs' Eyes, Ears and Overall Wellbeing VAUGHAN, ON, Oct. 24, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye ...